

COMPLETION OF US READER STUDY

Sydney: Artificial Intelligence and Medical Technology company Echo IQ Limited (“Echo IQ” or “the Company”) (ASX:EIQ) is pleased to announce that it has completed its US Reader Study.

The results from the Reader Study are now undergoing final statistical analysis and are expected to form part of the Company’s FDA 510(k) application, which will be submitted in April 2024. The FDA currently publicises its timeframe for decision response as being 90 days from lodgement of final application.

Echo IQ Chief Executive Officer Kimber Rothwell said: “Completion of our US Reader Study is a key step towards securing final FDA clearance for our cardiology decision-support technology and is an important milestone in Echo IQ’s commercial development.”

The Company also advises that its Chief Executive Officer, Kimber Rothwell has purchased 500,000 Echo IQ (ASX:EIQ) shares on-market.

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer
philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.